The Mitochondrial Peptide Revolution

MOTS-c, SS-31, and Humanin are rewriting our understanding of aging at the cellular level. Here's what the research actually shows.

Trend Report7 min readMarch 9, 2026

Peptides From Your Own Mitochondria

Most peptides in the Atlas are synthetic — designed in labs, manufactured, and administered. But MOTS-c, SS-31 (elamipretide), and Humanin belong to a different category entirely. These are mitochondrial-derived peptides (MDPs) — short peptides encoded within the mitochondrial genome that your body already produces. This distinction matters because it changes the therapeutic framing from "adding something foreign" to "restoring something that declines with age." Mitochondrial function deteriorates predictably as we get older, and MDP levels decline in parallel. The research question isn't whether these peptides do something useful — it's whether supplementing them can meaningfully slow or reverse age-related decline.

MOTS-c: The Exercise Mimetic

MOTS-c has generated excitement as a potential exercise mimetic — it activates AMPK, the same energy-sensing pathway triggered by physical activity. In animal models, MOTS-c improves insulin sensitivity, reduces obesity, and enhances exercise capacity even in aged mice. The mechanistic story is compelling: MOTS-c translocates to the nucleus under metabolic stress and directly regulates gene expression related to glucose metabolism and antioxidant defense. It's not just a signaling molecule — it's a transcription factor that your mitochondria deploy when energy demands increase. Human data is still early but growing. Observational studies show MOTS-c levels correlate inversely with age and metabolic disease. Interventional trials are now beginning, and the question is whether exogenous MOTS-c can replicate in humans what it does in mice.

SS-31 (Elamipretide): The Clinical Leader

SS-31 is the most clinically advanced of the mitochondrial peptides, having completed multiple Phase II and Phase III trials. Unlike MOTS-c and Humanin, SS-31 is synthetic — designed to target cardiolipin in the inner mitochondrial membrane and restore electron transport chain function. The clinical data is mixed but instructive. In Barth syndrome (a rare mitochondrial cardiomyopathy), elamipretide showed functional improvement in a Phase II/III trial (TAZPOWER), with 168-week open-label extension data confirming sustained benefit. This led to FDA approval of elamipretide for Barth syndrome in 2025 — making it the first approved mitochondria-targeted peptide therapy. In the MMPOWER-3 trial for primary mitochondrial myopathy, overall results were mixed, though post hoc analysis identified genotype-specific responders. In age-related macular degeneration, results were less clear. A single-dose randomized trial in older adults showed elamipretide improved mitochondrial ATP production in skeletal muscle. What SS-31 teaches us is that mitochondrial-targeted therapy works — but the challenge is finding the right patient populations. Mitochondrial dysfunction is ubiquitous in aging, but the degree to which any single organ benefits from targeted therapy varies.

Humanin: The Neuroprotective Signal

Humanin was the first mitochondrial-derived peptide discovered (2001), and its story begins with Alzheimer's disease. It was identified in a screen for factors that protect neurons from amyloid-beta toxicity. A landmark 2003 study in Nature demonstrated that Humanin suppresses apoptosis by directly interfering with Bax activation — providing a clear mechanistic basis for its cytoprotective effects. Since then, Humanin has shown cytoprotective effects across an extraordinary range of models: cardiovascular disease, diabetes, cancer, and neurodegeneration. It appears to function as a broad-spectrum cellular stress response signal. Animal studies have shown Humanin regulates both lifespan and healthspan, with long-lived species like naked mole rats exhibiting higher Humanin levels. The paradox of Humanin is that its effects are so broad that it's been difficult to identify a specific therapeutic niche. In human observational data, higher circulating Humanin levels are associated with better cognitive function in the elderly and lower cardiovascular risk. A 2023 systematic review cataloged Humanin's pathophysiological roles across aging-related conditions. But translating this into a therapeutic strategy remains a challenge — do you supplement Humanin directly, or find ways to boost endogenous production?

The Bigger Picture: Mitochondria as a Therapeutic Target

The mitochondrial peptide field represents a paradigm shift in how we think about aging interventions. Rather than targeting downstream consequences (wrinkles, muscle loss, cognitive decline), these peptides target the upstream driver — mitochondrial dysfunction itself. The evidence is strongest at the mechanistic level: we understand what these peptides do, how they work, and why they decline with age. The gap is in large-scale human outcomes data. SS-31 has now crossed the regulatory threshold with FDA approval for Barth syndrome, but even its broader results highlight how difficult it is to translate mitochondrial science into reliable clinical benefits across diverse populations. Beyond these three peptides, the MDP family continues to grow — small humanin-like peptides (SHLPs) and other mitochondrial open reading frame-encoded peptides are being characterized, each with distinct signaling properties. A 2020 review in the American Journal of Physiology mapped the emerging roles of MDPs in energy metabolism, suggesting this field has much further to expand. For the peptide-curious, this is a space to watch closely. The science is real, the rationale is sound, and the first regulatory approval has arrived — but we're still in the early chapters of proving these therapies work broadly in practice.

Key Findings

MOTS-c activates AMPK (the exercise pathway) and improves insulin sensitivity and exercise capacity in aged animal models
MOTS-c translocates to the nucleus under metabolic stress to directly regulate gene expression — functioning as a mitochondria-to-nucleus signaling molecule (Cell Metabolism, 2018)
SS-31 (elamipretide) received FDA approval for Barth syndrome in 2025, making it the first approved mitochondria-targeted peptide therapy
A single dose of elamipretide improved mitochondrial ATP production in older adult skeletal muscle in a randomized trial (PLoS One, 2021)
Humanin levels decline with age and correlate inversely with Alzheimer's risk and cardiovascular disease in observational studies
Humanin regulates both lifespan and healthspan in animal models, with long-lived species exhibiting higher circulating levels (Aging, 2020)
All three MDPs decline measurably with age, supporting the "restoration" rather than "enhancement" framing

Limitations & Caveats

MOTS-c has no published interventional human trial data yet — most evidence is preclinical or observational
SS-31 clinical results have been mixed across indications — the MMPOWER-3 trial for primary mitochondrial myopathy did not meet its primary endpoint, though genotype-specific responders were identified
SS-31's FDA approval is limited to Barth syndrome, a rare genetic disorder; broader anti-aging applications remain unproven
Humanin's broad cytoprotective effects make it difficult to design focused clinical trials
Most Humanin evidence comes from animal models and observational human data; no large interventional trials have been completed
Long-term safety of exogenous mitochondrial peptide supplementation is unknown

Sources

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Preclinical2015Cell Metabolism

The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress

Preclinical2018Cell Metabolism

MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis

Preclinical2021Nature Communications

A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism

Randomized Controlled Trial2021Genetics in Medicine

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER

Randomized Controlled Trial2024Genetics in Medicine

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial

Randomized Clinical Trial2023Neurology

In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial

Randomized Controlled Trial2021PLoS One

Elamipretide: First Approval

Review2026Drugs

Humanin peptide suppresses apoptosis by interfering with Bax activation

Preclinical2003Nature

10.